Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital — New Research Emphasizes Econo

Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital — New Research Emphasizes Economic Growth

NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorman Products, Inc. (NASDAQ:DORM), Arch Capital Group Ltd. (NASDAQ:ACGL), Acacia Communications, Inc. (NASDAQ:ACIA), UROGEN PHARMA (NASDAQ:URGN), CyrusOne Inc (NASDAQ:CONE), and TCP Capital Corp. (NASDAQ:TCPC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

DORM DOWNLOAD: http://Fundamental-Markets.com/register/?so=DORM
ACGL DOWNLOAD: http://Fundamental-Markets.com/register/?so=ACGL
ACIA DOWNLOAD: http://Fundamental-Markets.com/register/?so=ACIA
URGN DOWNLOAD: http://Fundamental-Markets.com/register/?so=URGN
CONE DOWNLOAD: http://Fundamental-Markets.com/register/?so=CONE
TCPC DOWNLOAD: http://Fundamental-Markets.com/register/?so=TCPC

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Dorman Products, Inc. (NASDAQ:DORM), Arch Capital Group Ltd. (NASDAQ:ACGL), Acacia Communications, Inc. (NASDAQ:ACIA), UROGEN PHARMA (NASDAQ:URGN), CyrusOne Inc (NASDAQ:CONE), and TCP Capital Corp. (NASDAQ:TCPC) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed April 11th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

DORMAN PRODUCTS, INC. (DORM) REPORT OVERVIEW

Dorman Products' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Dorman Products reported revenue of $227.72MM vs $229.10MM (down 0.60%) and basic earnings per share $0.66 vs $0.84 (down 21.43%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Dorman Products reported revenue of $903.22MM vs $859.60MM (up 5.07%) and basic earnings per share $3.14 vs $3.07 (up 2.28%). Dorman Products is expected to report earnings on May 1st, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.85. The estimated EPS forecast for the next fiscal year is $4.61 and is expected to report on February 25th, 2019.

To read the full Dorman Products, Inc. (DORM) report, download it here: http://Fundamental-Markets.com/register/?so=DORM

-----------------------------------------

ARCH CAPITAL GROUP LTD. (ACGL) REPORT OVERVIEW

Arch Capital Group's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Arch Capital Group reported revenue of $1,421.11MM vs $988.23MM (up 43.80%) and basic earnings per share $1.51 vs $0.51 (up 196.08%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Arch Capital Group reported revenue of $5,627.38MM vs $4,463.56MM (up 26.07%) and basic earnings per share $4.21 vs $5.50 (down 23.45%). Arch Capital Group is expected to report earnings on May 1st, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $1.42. The estimated EPS forecast for the next fiscal year is $6.90 and is expected to report on February 11th, 2019.

To read the full Arch Capital Group Ltd. (ACGL) report, download it here: http://Fundamental-Markets.com/register/?so=ACGL

-----------------------------------------

ACACIA COMMUNICATIONS, INC. (ACIA) REPORT OVERVIEW

Acacia Communications' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Acacia Communications reported revenue of $86.60MM vs $142.43MM (down 39.19%) and basic earnings per share -$0.53 vs $1.85. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Acacia Communications reported revenue of $385.17MM vs $478.41MM (down 19.49%) and basic earnings per share $0.99 vs $3.77 (down 73.74%). Acacia Communications is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.86. The estimated EPS forecast for the next fiscal year is $0.89 and is expected to report on February 28th, 2019.

To read the full Acacia Communications, Inc. (ACIA) report, download it here: http://Fundamental-Markets.com/register/?so=ACIA

-----------------------------------------

UROGEN PHARMA (URGN) REPORT OVERVIEW

UROGEN PHARMA's Recent Financial Performance

For the twelve months ended December 31st, 2017 vs December 31st, 2016, UROGEN PHARMA reported revenue of $8.16MM vs $17.53MM (down 53.46%) and basic earnings per share -$2.14 vs -$1.91. UROGEN PHARMA is expected to report earnings on June 21st, 2018. The report will be for the fiscal period ending March 31st, 2018. The estimated EPS forecast for the next fiscal year is -$2.74 and is expected to report on March 21st, 2019.

To read the full UROGEN PHARMA (URGN) report, download it here: http://Fundamental-Markets.com/register/?so=URGN

-----------------------------------------

CYRUSONE INC (CONE) REPORT OVERVIEW

CyrusOne's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, CyrusOne reported revenue of $180.50MM vs $137.40MM (up 31.37%) and basic earnings per share $0.03 vs $0.01 (up 200.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, CyrusOne reported revenue of $672.00MM vs $529.10MM (up 27.01%) and basic earnings per share -$0.95 vs $0.24. CyrusOne is expected to report earnings on May 2nd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.72. The estimated EPS forecast for the next fiscal year is $3.77 and is expected to report on February 20th, 2019.

To read the full CyrusOne Inc (CONE) report, download it here: http://Fundamental-Markets.com/register/?so=CONE

-----------------------------------------

TCP CAPITAL CORP. (TCPC) REPORT OVERVIEW

TCP Capital's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, TCP Capital reported revenue of $47.11MM vs $39.53MM (up 19.18%) and basic earnings per share $0.22 vs $0.44 (down 50.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, TCP Capital reported revenue of $175.97MM vs $148.18MM (up 18.75%) and basic earnings per share $1.19 vs $1.50 (down 20.67%). TCP Capital is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.47. The estimated EPS forecast for the next fiscal year is $1.60 and is expected to report on February 26th, 2019.

To read the full TCP Capital Corp. (TCPC) report, download it here: http://Fundamental-Markets.com/register/?so=TCPC

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.